HomeCompareYGYI vs PFE

YGYI vs PFE: Dividend Comparison 2026

YGYI yields 18018.02% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YGYI wins by $18633001307266260992.00M in total portfolio value
10 years
YGYI
YGYI
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full YGYI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — YGYI vs PFE

📍 YGYI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYGYIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YGYI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YGYI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YGYI
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, YGYI beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YGYI + PFE for your $10,000?

YGYI: 50%PFE: 50%
100% PFE50/50100% YGYI
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

YGYI
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-4.4
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YGYI buys
0
PFE buys
0
No recent congressional trades found for YGYI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYGYIPFE
Forward yield18018.02%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$18633001307266260992.00M$49.6K
Annual income after 10y$18,431,768,966,926,280,000,000,000.00$26,258.71
Total dividends collected$18619711198521020416.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: YGYI vs PFE ($10,000, DRIP)

YearYGYI PortfolioYGYI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,812,502$1,801,801.80$9,153$693.39+$1.80MYGYI
2$307,151,434$305,212,057.22$8,593$849.25+$307.14MYGYI
3$48,667,022,851$48,338,370,816.14$8,336$1,066.78+$48667.01MYGYI
4$7,210,053,431,136$7,157,979,716,686.14$8,437$1,384.80+$7210053.42MYGYI
5$998,798,584,418,300$991,083,827,246,983.60$9,013$1,875.40+$998798584.41MYGYI
6$129,380,351,742,642,780$128,311,637,257,315,230.00$10,306$2,680.72+$129380351742.63MYGYI
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$12,820$4,101.38+$15672057030122.30MYGYI
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$17,673$6,826.70+$1775286122699574.75MYGYI
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$27,543$12,591.86+$188067607794372832.00MYGYI
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$49,560$26,258.71+$18633001307266260992.00MYGYI

YGYI vs PFE: Complete Analysis 2026

YGYIStock

Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. It operates in three segments: Direct Selling, Commercial Coffee, and Commercial Hemp. The company offers nutritional supplements, gourmet coffee, weight management products, skincare and cosmetics, health and wellness, packaged foods, lifestyle products, pet care, digital products, telecare health services, apparel and fashion accessories, and business lending products. It also produces and sells coffee products under the Café La Rica, Café Alma, Josie's Java House, Javalution Urban Grind, Javalution Daily Grind, and Javalution Royal Roast brands; and produces and markets a line of coffees under the JavaFit brand directly to consumers. In addition, it offers CBD oils from hemp stock. The company sells coffee and equipment to wellness and retirement communities, and various cruise lines and coffee service operators, as well as through distribution network. Youngevity International, Inc. also markets its products through a range of consumer Websites, such as youngevity.com; ygyi.com; heritagemakers.com; hempfx.com; clrroasters.com; cafelarica.com; javalution.com. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013. Youngevity International, Inc. was founded in 1996 and is headquartered in Chula Vista, California.

Full YGYI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this YGYI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YGYI vs SCHDYGYI vs JEPIYGYI vs OYGYI vs KOYGYI vs MAINYGYI vs JNJYGYI vs MRKYGYI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.